Clinical Trial Update: Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating repeated administration of a 200-mcg dose of IPP-201101 plus standard of care in systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• IPP-201101 (IPP-201101)

Snippet

Sponsor: ImmuPharma | Conditions: Lupus Erythematosus, Systemic | Phase 3 | Status: COMPLETED